As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα, has become paramount in the treatment of atopic dermatitis, and its use in autoimmune bullous diseases was theorized in 2019 [2]. This evidence concerns the gene IL4R and atopic eczema.